Company research
Co-Diagnostics, Inc.
CIK 1692415Updated Sep 26, 2026
SecurityCODX · NASDAQ · equity
CODX price & chart
Loading TradingView…
NASDAQ:CODX on TradingView ↗About the company
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
In the news
Co-Diagnostics Reports Third Quarter 2025 Financial Results News provided by Co-Diagnostics Nov 13, 2025, 16:01 ET Share this article Share to X Share this article Share to X SALT LAKE CITY , Nov. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX ) ("Co-Diagnostics," "Co-Dx," or "the Compa ↗
Recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
PRE 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 24,742,585Source | 63,999,919Source | 95,320,660Source | 123,086,280Source |
| Property, Plant and Equipment, NetUSD | 2,272,098Source | 2,761,280Source | 3,035,729Source | 2,539,483Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,219,000Source | 26,101,000Source | 26,403,667Source | 26,768,333Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,884,607Source | 2,936,544Source | 14,916,878Source | 22,973,803Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 190,375Source | 132,570Source | 303,926Source | 3,453,723Source |
| Inventory, NetUSD | 992,397Source | 1,072,724Source | 1,664,725Source | 5,310,473Source |
| Assets, CurrentUSD | 13,693,465Source | 32,291,698Source | 62,141,108Source | 92,733,670Source |
| Prepaid Expense and Other Assets, CurrentUSD | 581,527Source | 1,338,762Source | 1,597,114Source | 761,186Source |
| Operating Lease, Right-of-Use AssetUSD | 1,207,453Source | 2,114,876Source | 2,966,774Source | 372,115Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,113,921Source | 9,688,001Source | 9,307,045Source | 8,566,288Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 67,700Source | 37,902Source | 36,108Source | 34,754Source |
| Additional Paid in CapitalUSD | 116,510,298Source | 102,472,210Source | 96,808,436Source | 88,472,934Source |
| Retained Earnings (Accumulated Deficit)USD | -80,373,539Source | -33,040,842Source | 4,598,166Source | 39,931,030Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 418,443Source | 146,700Source | 293,140Source |
| Stockholders' Equity Attributable to ParentUSD | 20,628,664Source | 54,311,918Source | 86,013,615Source | 114,519,992Source |
| Liabilities and EquityUSD | 24,742,585Source | 63,999,919Source | 95,320,660Source | 123,086,280Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,539,620Source | 7,315,718Source | 5,747,570Source | 3,873,424Source |
| Operating Lease, Liability, CurrentUSD | 662,258Source | 915,619Source | 838,387Source | 297,209Source |
| Accounts Payable, CurrentUSD | 1,878,225Source | 3,294,254Source | 1,482,109Source | 952,297Source |
| Operating Lease, Liability, NoncurrentUSD | 574,301Source | 1,236,560Source | 2,152,180Source | 50,708Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 2,417,987Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 865,301Source | 2,562,169Source | 2,172,959Source | 934,447Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 1,377,266Source | 1,230,474Source | 1,282,718Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,248,053Source | 5,434,904Source | 8,336,855Source | 7,543,223Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 31,799Source | -186,391Source | -2,536,988Source | -14,956,529Source |
| Increase (Decrease) in InventoriesUSD | -131,271Source | -265,489Source | -413,140Source | 3,525,210Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | -2,417,987Source | -4,810,457Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,136,927Source | -29,155,045Source | -22,081,865Source | 6,568,737Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 26,273,407Source | 17,070,797Source | 15,388,869Source | -58,168,172Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 700,047Source | 748,352Source | 1,365,306Source | 1,427,512Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 1,363,929Source | 14,211,866Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,811,583Source | 103,914Source | -1,363,929Source | -14,033,996Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,948,063Source | -11,980,334Source | -8,056,925Source | -65,633,431Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | -858,870Source | — | 55,975Source | 4,498,742Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,248,053Source | 5,434,904Source | 8,336,855Source | 7,543,223Source |
| Gain (Loss) on Disposition of AssetsUSD | -82,421Source | 8,291Source | -2,578Source | -138,117Source |
| Gain (Loss) on Sale of InvestmentsUSD | -46,301Source | -186,067Source | 100,703Source | -332,969Source |
| General and Administrative ExpenseUSD | 9,058,283Source | 16,157,152Source | 14,279,441Source | 14,262,963Source |
| Goodwill, Impairment LossUSD | — | — | — | 15,388,546Source |
| Income Tax Expense (Benefit)USD | -1,615,978Source | 57,368Source | -2,777,691Source | -4,608,985Source |
| Inventory Write-downUSD | -50,944Source | 326,512Source | 3,233,281Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | 418,443Source | 146,700Source | 389,241Source |
| Net Income (Loss) Attributable to ParentUSD | -46,895,936Source | -37,639,008Source | -35,332,865Source | -14,238,249Source |
| Nonoperating Income (Expense)USD | 1,653,438Source | 2,499,670Source | 4,595,678Source | 8,132,602Source |
| Operating ExpensesUSD | 50,565,464Source | 42,997,346Source | 45,333,323Source | 55,716,953Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 177,870Source |
| Proceeds from Stock Options ExercisedUSD | 12,500Source | — | — | — |
| Realized Investment Gains (Losses)USD | 683,365Source | 870,745Source | 2,243,059Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 3,915,160Source | 6,812,038Source | 34,218,209Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 622,489Source | 3,915,160Source | 6,812,038Source | 34,218,209Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -50,165,352Source | -40,081,310Source | -42,706,234Source | -26,979,836Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -48,511,914Source | -37,581,640Source | -38,110,556Source | -18,847,234Source |
| Income Tax Expense (Benefit)USD | -1,615,978Source | 57,368Source | -2,777,691Source | -4,608,985Source |
| Net Income (Loss) Attributable to ParentUSD | -46,895,936Source | -37,639,008Source | -35,332,865Source | -14,238,249Source |
| Earnings Per Share, BasicUSD per share | -35.25Source | -1.24Source | -1.2Source | -0.45Source |
| Earnings Per Share, DilutedUSD per share | -35.25Source | -1.24Source | -1.2Source | -0.45Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,330,200Source | 30,335,350Source | 29,346,599Source | 31,479,028Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,330,200Source | 30,335,350Source | 29,346,599Source | 31,479,028Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,106,808Source | 1,377,266Source | 1,230,474Source | 1,282,718Source |
| General and Administrative ExpenseUSD | 9,058,283Source | 16,157,152Source | 14,279,441Source | 14,262,963Source |
| Goodwill, Impairment LossUSD | — | — | — | 15,388,546Source |
| Gross ProfitUSD | 400,112Source | 2,916,036Source | 2,627,089Source | 28,737,117Source |
| Interest Income, OtherUSD | 292,932Source | 1,091,825Source | 1,161,913Source | 704,044Source |
| Nonoperating Income (Expense)USD | 1,653,438Source | 2,499,670Source | 4,595,678Source | 8,132,602Source |
| Operating ExpensesUSD | 50,565,464Source | 42,997,346Source | 45,333,323Source | 55,716,953Source |
| Realized Investment Gains (Losses)USD | 683,365Source | 870,745Source | 2,243,059Source | — |
| Research and Development ExpenseUSD | 19,137,242Source | 20,979,589Source | 22,962,593Source | 17,438,098Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 3,915,160Source | 6,812,038Source | 34,218,209Source |
| Selling and Marketing ExpenseUSD | 2,381,131Source | 4,483,339Source | 6,860,815Source | 7,344,628Source |
Filing attachments
ex99-1.htm · 8-K · 2026-09-16
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled Capabilities SALT LAKE CITY, August 13, 2026 - Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx,” or “the Company”), a molecular diagnostics company with a unique, patented platfor…
Read attachment ↗ex4-1.htm · 8-K · 2026-07-31
EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-1.htm · 8-K · 2026-05-21
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗ex4-2.htm · 8-K · 2026-05-21
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗